Post-Hoc Live

Endpoints News
  • 0.0(0개의 평가)
  • 뉴스
  • 주 2회 업데이트

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

  1. 6일 전

    Live from Boston: How pharma thinks about China

    As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the large drugmaker perspective on acquisitions, R&D, and how the industry could change in the years to come.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

  2. 6일 전

    Live from Boston: Investor math versus industrial priority

    Should investors embrace China’s fast-moving, fast-growing biotech sector, or should there be barriers to protect and preserve an industry that the US has dominated for decades? Ginkgo Bioworks CEO Jason Kelly, RA Capital Management's Peter Kolchinsky, and MIT professor Fiona Murray debate all sides of the flashpoint issue.Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

  3. 6일 전

    Live from Boston: Has China changed how we build companies?

    In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? Strand Therapeutics CEO Jake Becraft and Roivant Sciences CEO Matt Gline discussed what actually counts as innovation, and if where the innovation happens matters for how the industry brings programs to patients. Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.

  4. 8월 4일

    The case for — and against — an AZ-BMS megadeal

    AstraZeneca and Bristol Myers Squibb are reportedly in talks to combine, which would be one of the largest mergers the biopharma industry has ever seen. What could each company get out of the deal, and what would this deal mean for the industry overall? And are megamergers back? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

  5. 7월 16일

    Record IPOs — with Parabilis and Kailera’s CEOs

    Kailera broke records with its $625 million IPO in April. But its high-water mark didn’t last long — in June, Parabalis made a $670 million debut, putting its own name on top of the record books. On Post-Hoc Live, we’re joined by Ron Renaud and Mathai Mammen, the CEOs of the companies, to talk about what it took to reach those heights.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

  6. 6월 22일

    Are the China hawks winning?

    WuXi is back on the Pentagon’s blacklist. The United States Treasury might restrict investments in Chinese biotech. Despite wave after wave of big pharma announcements around partnerships with China, the protectionist voices are taking up more airtime. Where are the winds blowing, and what material impact could this all have? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

  7. 6월 9일

    How much is everyone in biopharma getting paid?

    CEO pay keeps going up, and up, and up. What do the pay ratios at pharmas say about the state of the industry as a whole, and how do the eye-popping numbers affect global competition? On Post-Hoc Live, we’ll take you behind the scenes of Endpoints’ annual biopharma compensation report, which breaks down pay for top execs and median workers.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

  8. 5월 27일

    How to stabilize US biotech — with Dr. Jeremy Levin

    Jeremy Levin has seen the biopharma industry from practically every vantage point. Now, with decades of experience under his belt, he’s out front in the chorus of veterans sounding the alarm about threats to US dominance in biotech. He joins Post-Hoc Live to talk about China, US policy, and how to stem the bleeding.  Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D

모두 보기(48개)

예고편

소개

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

정보

  • 제작진
    Endpoints News
  • 방송 연도
    2025년 - 2026년
  • 에피소드
    48
  • 등급
    무삭제판
  • 저작권
    © Endpoints News
  • 웹사이트 보기
    Post-Hoc Live

좋아할 만한 다른 항목